Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)

What Was Tested

This registered phase 2 trial tested Vitamin D, K2, Magnesium and Zinc.

It had 1 arm (groups): Vitamin K2 (MK7) (experimental).

The registry classes the interventions as dietary supplement.

Who Took Part

The registry lists 60 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Functional renal graft. Stable renal function for at least 3 months prior to enrollment.

The full record lists 2 inclusion and 9 exclusion criteria; among the exclusions: history of thrombotic events; diagnosed coagulopathy; cardiovascular event in the past month prior to enrollment.

How the Study Was Run

The set-up was single-group and open-label.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2015-03 with completion listed for 2016-05.

It ran at 1 site in Lebanon.

Its stated primary purpose is treatment.

What Was Measured

It also tracked 3 secondary outcomes, for example Change From Baseline in Central Pressure by Ambulatory Hemodynamic Measurement (Mobil-O-Graph) at 8 Weeks, Change From Baseline in Augmentation Index by Ambulatory Hemodynamic Measurement (Mobil-O-Graph) at 8 Weeks and Change From Baseline in Blood Concentration of Dephosphorylated-uncarboxylated Matrix Gla Protein (Dp-ucMGP) at 8 Weeks.

What This Means in Plain Language

Put simply, this is a phase 2 trial of Vitamin D, K2, Magnesium and Zinc in 60 people.

The trial is marked completed; results are posted on the registry, and this page does not restate them.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.